Clinical Trial Update: Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the combination of pembrolizumab and trametinib for patients with stage IV non-small cell lung cancer, including KRAS-mutant disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• MEKINIST (trametinib)

Snippet

Sponsor: Jonathan Riess | Conditions: KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2025-05-21